article thumbnail

Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

Digital Health Global

About Koneksa Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. These adverse events often lead to hospitalizations and treatment interruptions that can reduce treatment efficacy.

article thumbnail

Merative formerly IBM Watson Health poised to launch raft of new products in 2025

Lloyd Price

With significant investments and a focus on innovation, Merative is poised to play a major role in shaping the future of healthcare data analytics and technology. Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.

article thumbnail

Koneksa Announces Partnership with Beacon Biosignals for Clinical Trial in Sleep and Neurologic Disorders Using EEG Biomarkers

Digital Health Global

“The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re We’re on a mission to revolutionize drug development in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights.

article thumbnail

Key Themes from the Morgan Stanley 22nd Annual Global Healthcare Conference 2024

Lloyd Price

The conference explored the advancements in precision medicine and its implications for healthcare delivery. Biopharma Innovation and Drug Development: The development of innovative drugs and therapies remains a key focus in the healthcare industry.

article thumbnail

How can Palantir win 'hearts and minds' to deliver the NHS England Federated Data Platform?

Lloyd Price

By implementing these strategies, Palantir can effectively address public concerns, build trust, and gain acceptance for its role in delivering the NHS Federated Data Platform, ultimately contributing to improved patient care and healthcare outcomes in England. What are a few likely scenarios for Palantir in Healthcare?

article thumbnail

HLTH 2024: What are the key talking points likely to be?

Lloyd Price

Overall, HLTH 2024 is expected to be a thought-provoking and informative event that will shape the future of healthcare. Nelson Advisors work with Healthcare Technology Founders, Owners and Investors to assess whether they should 'Build, Buy, Partner or Sell' in order to maximise shareholder value.